Ryan Dietz

Ryan Dietz is a partner in TIO Bioventures, bringing more than 20 years of experience in technology evaluation, intellectual property generation, licensing and partnering transactions, and company formation efforts to the firm.
Ryan also serves as Vice President, Corporate Development of TIO Bioventures’ flagship portfolio company Treadwell Therapeutics.
Prior to joining TIO, Ryan was a licensing executive with Boston Children’s Hospital, where he oversaw the hospital’s two largest research programs across all stages of development.
During his industry career, Ryan led technology development and intellectual property generation efforts for various prominent start-up biotechnology and pharmaceutical companies including Moderna, Scholar Rock, Magenta Therapeutics, and Morphic Therapeutic.
Each of these companies successfully completed IPOs in 2018 or 2019, including the largest IPO in biotechnology history with Moderna raising $620M at a $7.5B valuation.
Ryan also has extensive business development and alliance management experience and is an inventor and developer of multiple consumer products for musicians.
He holds a Bachelor of Arts degree in psychology and criminal justice from Indiana University Bloomington, and a JD in intellectual property and licensing from Suffolk University Law School.